Overview

Anlotinib Combined With STUPP for MGMT Nonmethylated Glioblastoma

Status:
Recruiting

Trial end date:
2023-12-01

Target enrollment:
0

Participant gender:
All

Summary

The purpose of this study is to test the efficacy and safety of Anlotinib in combination with STUPP regimen for MGMT promoter nonmethylated glioblastoma.

Phase:

Phase 2

Accepts Healthy Volunteers?

Details

Lead Sponsor:

Second Affiliated Hospital, School of Medicine, Zhejiang University

Treatments:

Temozolomide

Criteria

Inclusion Criteria:

1. Aged 18-70 years,

2. Histologically proven diagnosis of glioblastoma (WHO grade IV),

3. Have received standard STUPP treatment plan,

4. Gross resection or partial resection of the tumor (confirmed by MRI)> 50%,

5. The pathological tissue specimens are detected as MGMT unmethylated,6.Karnofsky
performance status ≥ 60,

6. No previous radiotherapy, chemotherapy, immunotherapy or biotherapy 7.Adequate bone
marrow function: Hemoglobin ≥ 100g/L，Platelets ≥ 80×109/L，Absolute neutrophil count
(ANC) ≥ 1.5×109/L

8.Adequate renal function: Serum creatinine ≤ 1.25 x UNL (upper normal limit) or creatinine
clearance ≥ 60 ml/min 9.Adequate hepatic function: serum bilirubin ≤ 1.5 x UNL, AST and ALT
≤ 2.5 x UNL，ALP≤5x UNL 10.For females of child-bearing potential, negative serum pregnancy
test within 14 days prior to registration. Women of childbearing potential and male
participants must practice adequate contraception during participation in the study and
within 8 weeks after the last administration of the drug 11.Able to provide written
informed consent

Exclusion Criteria:

1. Recurrent or multiple malignant gliomas

2. Subtentorial glioblastoma or metastatic lesions outside the skull

3. Have received radiotherapy, chemotherapy or other anti-tumor drugs for the disease
before surgery

4. Previously received radiation therapy for the head and neck cancer

5. Have received any antibody treatment before

6. Contraindication of radiotherapy and chemotherapy defined as follows: Acute bacterial
or fungal infection，Unstable angina and/or congestive heart failure within the last 6
months，co-morbidity with immunosuppressive therapy

7. Evidence of bleeding diathesis or coagulopathy

8. Prior invasive malignancy (except for non-melanomatous skin cancer or carcinoma in
situ of cervix)